Report: Developing Opportunities within Mattel, Achillion Pharmaceuticals, Celgene, Adesto Technologies, New Residential Investment, and Entegris — Future Expectations, Projections Moving into 2019

04-04-2019

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Mattel, Inc. (NASDAQ:MAT), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Celgene Corporation (NASDAQ:CELG), Adesto Technologies Corporation (NASDAQ:IOTS), New Residential Investment Corp. (NYSE:NRZ), and Entegris, Inc. (NASDAQ:ENTG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MAT DOWNLOAD: https://Capital-Review.com/register/?so=MAT
ACHN DOWNLOAD: https://Capital-Review.com/register/?so=ACHN
CELG DOWNLOAD: https://Capital-Review.com/register/?so=CELG
IOTS DOWNLOAD: https://Capital-Review.com/register/?so=IOTS
NRZ DOWNLOAD: https://Capital-Review.com/register/?so=NRZ
ENTG DOWNLOAD: https://Capital-Review.com/register/?so=ENTG

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Mattel, Inc. (NASDAQ:MAT), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Celgene Corporation (NASDAQ:CELG), Adesto Technologies Corporation (NASDAQ:IOTS), New Residential Investment Corp. (NYSE:NRZ), and Entegris, Inc. (NASDAQ:ENTG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

MATTEL, INC. (MAT) REPORT OVERVIEW

Mattel's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Mattel reported revenue of $1,524.28MM vs $1,610.87MM (down 5.38%) and analysts estimated basic earnings per share $0.04 vs -$0.83. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Mattel reported revenue of $4,510.85MM vs $4,881.95MM (down 7.60%) and analysts estimated basic earnings per share -$1.54 vs -$3.07. Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.60. The estimated EPS forecast for the next fiscal year is $0.03 and is expected to report on February 6th, 2020.

To read the full Mattel, Inc. (MAT) report, download it here: https://Capital-Review.com/register/?so=MAT

-----------------------------------------

ACHILLION PHARMACEUTICALS, INC. (ACHN) REPORT OVERVIEW

Achillion Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.15. The estimated EPS forecast for the next fiscal year is -$0.74 and is expected to report on March 5th, 2020.

To read the full Achillion Pharmaceuticals, Inc. (ACHN) report, download it here: https://Capital-Review.com/register/?so=ACHN

-----------------------------------------

CELGENE CORPORATION (CELG) REPORT OVERVIEW

Celgene's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Celgene reported revenue of $4,037.00MM vs $3,483.00MM (up 15.91%) and analysts estimated basic earnings per share $1.52 vs -$0.10. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Celgene reported revenue of $15,281.00MM vs $13,003.00MM (up 17.52%) and analysts estimated basic earnings per share $5.65 vs $3.77 (up 49.87%). Analysts expect earnings to be released on May 3rd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.61. The estimated EPS forecast for the next fiscal year is $12.12 and is expected to report on January 30th, 2020.

To read the full Celgene Corporation (CELG) report, download it here: https://Capital-Review.com/register/?so=CELG

-----------------------------------------

ADESTO TECHNOLOGIES CORPORATION (IOTS) REPORT OVERVIEW

Adesto Technologies' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Adesto Technologies reported revenue of $28.08MM vs $16.15MM (up 73.81%) and basic earnings per share -$0.27 vs $0.03. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Adesto Technologies reported revenue of $83.49MM vs $56.11MM (up 48.79%) and analysts estimated basic earnings per share -$0.85 vs -$0.31. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is -$0.10 and is expected to report on February 20th, 2020.

To read the full Adesto Technologies Corporation (IOTS) report, download it here: https://Capital-Review.com/register/?so=IOTS

-----------------------------------------

NEW RESIDENTIAL INVESTMENT CORP. (NRZ) REPORT OVERVIEW

New Residential Investment's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, New Residential Investment reported revenue of $441.13MM vs $512.35MM (down 13.90%) and analysts estimated basic earnings per share -$0.07 vs $0.96. For the twelve months ended December 31st, 2018 vs December 31st, 2017, New Residential Investment reported revenue of $2,192.82MM vs $1,944.03MM (up 12.80%) and analysts estimated basic earnings per share $2.82 vs $3.17 (down 11.04%). Analysts expect earnings to be released on April 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.58. The estimated EPS forecast for the next fiscal year is $2.32 and is expected to report on February 11th, 2020.

To read the full New Residential Investment Corp. (NRZ) report, download it here: https://Capital-Review.com/register/?so=NRZ

-----------------------------------------

ENTEGRIS, INC. (ENTG) REPORT OVERVIEW

Entegris' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Entegris reported revenue of $401.64MM vs $350.56MM (up 14.57%) and analysts estimated basic earnings per share $0.58 vs -$0.20. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Entegris reported revenue of $1,550.50MM vs $1,342.53MM (up 15.49%) and analysts estimated basic earnings per share $1.71 vs $0.60 (up 185.00%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.47. The estimated EPS forecast for the next fiscal year is $2.31 and is expected to report on February 4th, 2020.

To read the full Entegris, Inc. (ENTG) report, download it here: https://Capital-Review.com/register/?so=ENTG

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Latest news
Related news
Related shares
Mattel Inc
VOL 2,891,484
10.96 USD
0.13 / 1.20 %

Entegris Inc
VOL 920,389
36.15 USD
-0.89 / -2.40 %

Achillion Pharmaceuticals Inc
VOL 674,331
2.930 USD
-0.13 / -4.25 %

New Residential Investment Cor
VOL 419,930
16.53 USD
-0.09 / -0.54 %

Celgene Corporation
VOL 4
94.83 USD
-0.59 / -0.62 %